Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy

@article{Takane2006PharmacogeneticDO,
  title={Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy},
  author={Hiroshi Takane and Masanori Miyata and Naoto Burioka and Chiaki Shigemasa and Eiji Shimizu and Kenji Otsubo and Ichiro Ieiri},
  journal={Journal of Human Genetics},
  year={2006},
  volume={51},
  pages={822-826}
}
AbstractPravastatin is mainly taken up from the circulation into the liver via organic anion-transporting polypeptide 1B1 (SLCO1B1 gene product). We examined the contribution of genetic variants in the SLCO1B1 gene and other candidate genes to the variability of pravastatin efficacy in 33 hypercholesterolemic patients. In the initial phase of pravastatin treatment (8 weeks), heterozygous carriers of the SLCO1B1*15 allele had poor low-density lipoprotein cholesterol (LDL-C) reduction relative to… CONTINUE READING
22 Citations
17 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 22 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 17 references

Similar Papers

Loading similar papers…